C12N 2740/12022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/12022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 21 US grants and 20 published applications in this corpus.
Search patents in C12N- Granted patents
- 21
- Published applications
- 20
- Assignees
- 25
- Inventors
- 88
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 0 |
| 2006 | 2 | 0 |
| 2007 | 0 | 3 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 1 | 1 |
| 2024 | 2 | 2 |
| 2025 | 0 | 4 |
| 2026 | 3 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use29 Sep 2026US 12,747,270 B2Twilight Bioscience, Inc.
- Recombinant retroviral vectors for gene therapy25 Aug 2026US 12,716,074 B1United Arab Emirates University
- HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use4 Aug 2026US 12,698,309 B2Twilight Bioscience, Inc.
- Mammary tumor virus suppression25 Jun 2024US 12,016,844 B2Virago Vax Inc.
- Particle delivery systems7 May 2024US 11,976,277 B2Scribe Therapeutics Inc.
- Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use5 Feb 2026US 2026/0035414 A1Twilight Bioscience, Inc.
- Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use5 Feb 2026US 2026/0035415 A1Twilight Bioscience, Inc.
- Glycoproteins for pseudotyping retroviral vector particles25 Dec 2025US 2025/0388924 A1Medizinische Hochschule Hannover
- Modular betaretrovirus receptor attachment and cell entry proteins8 May 2025US 2025/0144238 A1
- Herv-k antibody, cell, vaccine, and drug therapeutics8 May 2025US 2025/0145693 A1SunnyBay BioTech, Inc.
Most cited
By later US patents
- Method for providing a cell culture from a transgenic non-human mammal30US 5,087,571 APresident and Fellows of Harvard College · 1992
- Retroviral superantigens, superantigen peptides, and methods of use9US 5,519,114 AUniversity of Florida Research Foundation, Inc. · 1996
- Testing method using transgenic mice expressing an oncogene8US 5,925,803 APresident and Fellows of Havard College · 1999
- Transgenic mouse carrying a non-infectious HIV genome7US 5,574,206 AL'Institut de Recherches Cliniques de Montreal · 1996
- Methods for stimulating immune responses in a host through the administration of superantigen peptides derived from human immunodeficiency virus type 1 Nef7US 5,968,514 AUniversity of Florida · 1999